OraSure Technologies, Inc.  

(Public, NASDAQ:OSUR)   Watch this stock  
Find more results for OSUR
0.00 (0.00%)
Aug 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.67 - 9.00
Open     -
Vol / Avg. 0.00/447,264.00
Mkt cap 475.33M
P/E 406.61
Div/yield     -
EPS 0.02
Shares 55.99M
Beta 1.65
Inst. own 80%
Nov 4, 2014
Q3 2014 OraSure Technologies Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 13, 2014
OraSure Technologies Inc at Canaccord Genuity Growth Conference
Aug 6, 2014
Q2 2014 OraSure Technologies Inc Earnings Call - Webcast
Aug 4, 2014
Q2 2014 OraSure Technologies, Inc. Earnings Release
Jun 24, 2014
OraSure Technologies Inc at JMP Securities Healthcare Conference
Jun 11, 2014
OraSure Technologies Inc Conference Call to provide an update on certain developments related to its OraQuick HCV
Jun 4, 2014
OraSure Technologies, Inc. at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 9.58% -11.31%
Operating margin 9.46% -12.29%
EBITD margin - -14.06%
Return on average assets 5.74% -5.96%
Return on average equity 6.44% -6.75%
Employees 293 -
CDP Score - -


United States - Map
+1-503-6416115 (Phone)
+1-610-8821830 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OraSure Technologies, Inc., is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company's oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The Company's diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. The Company operates in two segments: OraSure business and DNAG. On August 17, 2011, the Company completed the acquisition of DNA Genotek Inc. (DNAG).

Officers and directors

Douglas G. Watson Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Douglas A. Michels President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald H. Spair Chief Financial Officer, Chief Operating Officer, Director
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Anthony II Zezzo II Executive Vice President - Marketing and Sales
Age: 60
Bio & Compensation  - Reuters
Mark L. Kuna Senior Vice President - Finance, Controller, Assistant Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack E. Jerrett Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Eric Whitters Senior Vice President - R&D, Regulatory, Quality and Clinical Affairs
Age: 53
Bio & Compensation  - Reuters
Michael Celano Independent Director
Age: 55
Bio & Compensation  - Reuters
Ronny B. Lancaster Independent Director
Age: 62
Bio & Compensation  - Reuters
Gerald M. Ostrov Independent Director
Age: 64
Bio & Compensation  - Reuters